Investor Relations

Company Information

MiNK Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class invariant natural killer T (iNKT) cell therapies to transform the lives of patients with cancer.
Press Releases
May 10, 2022
Clinical updates from solid tumor cancers and ARDS with allo-agenT-797 are on track for 2H 2022 GMP manufacturing launch in 1H 2022 with target 10,000 doses/yr BCMA-CAR-iNKT and stromal-CAR-iNKT preclinical results 2H 2022 Ended First Quarter with $34.7M in cash with a projected 2022 cash burn of

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

SEC Filings

Form Description Filing date View
10-K

Annual report which provides a comprehensive overview of the company for the past year

View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
10-Q

Quarterly report which provides a continuing view of a company's financial position

View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
10-Q

Quarterly report which provides a continuing view of a company's financial position

View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
3

Initial filing by director officer or owner of more than ten percent.

View HTML

Data provided by Kaleidoscope.